MX2025001887A - Formas cristalinas de un inhibidor de pcsk9, composiciones y usos - Google Patents

Formas cristalinas de un inhibidor de pcsk9, composiciones y usos

Info

Publication number
MX2025001887A
MX2025001887A MX2025001887A MX2025001887A MX2025001887A MX 2025001887 A MX2025001887 A MX 2025001887A MX 2025001887 A MX2025001887 A MX 2025001887A MX 2025001887 A MX2025001887 A MX 2025001887A MX 2025001887 A MX2025001887 A MX 2025001887A
Authority
MX
Mexico
Prior art keywords
disease
crystalline forms
compositions
methods
pcsk9 inhibitor
Prior art date
Application number
MX2025001887A
Other languages
English (en)
Spanish (es)
Inventor
Jongrock Kong
Richard J Varsolona
Richard Desmond
Peter E Maligres
Fuh - Rong TSAY
Carlos Alberto Pons Siepermann
Artis Klapars
Lee Robison
Alfred Lee
Tiffany Piou
Lorenzo Codan
Patrick Larpent
Original Assignee
Merck Sharp & Dohme Llc
Werthenstein Biopharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc, Werthenstein Biopharma Gmbh filed Critical Merck Sharp & Dohme Llc
Publication of MX2025001887A publication Critical patent/MX2025001887A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2025001887A 2022-08-17 2025-02-14 Formas cristalinas de un inhibidor de pcsk9, composiciones y usos MX2025001887A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263371690P 2022-08-17 2022-08-17
US202263384298P 2022-11-18 2022-11-18
PCT/US2023/072326 WO2024040125A1 (en) 2022-08-17 2023-08-16 Crystalline forms of a pcsk9 inhibitor, compositions and uses

Publications (1)

Publication Number Publication Date
MX2025001887A true MX2025001887A (es) 2025-03-07

Family

ID=89942405

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025001887A MX2025001887A (es) 2022-08-17 2025-02-14 Formas cristalinas de un inhibidor de pcsk9, composiciones y usos

Country Status (10)

Country Link
US (1) US20260035411A1 (enExample)
EP (1) EP4573104A4 (enExample)
JP (1) JP7866141B2 (enExample)
KR (1) KR20250048468A (enExample)
CN (1) CN119731194A (enExample)
AU (1) AU2023325144A1 (enExample)
CO (1) CO2025001998A2 (enExample)
IL (1) IL319006A (enExample)
MX (1) MX2025001887A (enExample)
WO (1) WO2024040125A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026032253A1 (zh) * 2024-08-06 2026-02-12 石药集团中奇制药技术（石家庄）有限公司 环肽类似物及其制备方法和用途
WO2026101894A1 (en) * 2024-11-07 2026-05-15 Merck Sharp & Dohme Llc Process for preparing a peptide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250161677A (ko) 2018-06-21 2025-11-17 머크 샤프 앤드 돔 엘엘씨 Pcsk9 길항제 화합물
EP3810129B1 (en) 2018-06-21 2023-08-16 Merck Sharp & Dohme LLC Pcsk9 antagonist bicyclo-compounds
WO2019246405A1 (en) 2018-06-21 2019-12-26 Merck Sharp & Dohme Corp. Cyclic polypeptides for pcsk9 inhibition
EP4021919A1 (en) * 2019-08-30 2022-07-06 Merck Sharp & Dohme Corp. Pcsk9 antagonist compounds

Also Published As

Publication number Publication date
EP4573104A4 (en) 2026-08-05
WO2024040125A1 (en) 2024-02-22
AU2023325144A1 (en) 2025-01-30
CO2025001998A2 (es) 2025-03-17
JP2025527471A (ja) 2025-08-22
EP4573104A1 (en) 2025-06-25
CN119731194A (zh) 2025-03-28
JP7866141B2 (ja) 2026-05-26
US20260035411A1 (en) 2026-02-05
KR20250048468A (ko) 2025-04-08
IL319006A (en) 2025-04-01

Similar Documents

Publication Publication Date Title
EP4660303A3 (en) Pcsk9 antagonist compounds
EA200802288A1 (ru) Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови
WO2010005958A3 (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
TW200614983A (en) 5-substituted-2-phenylamino benzamides as MEK inhibitors
TN2012000413A1 (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
TNSN08367A1 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
ECSP077357A (es) Procedimiento para la preparación de 4-{4-[cloro-3-(trifluorometil) fenil] amino}carbonil)amino]fenoxi}n-metilpiridina-2-carboxamida
MY150787A (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of prevention of diabetes
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
BR112012020704A2 (pt) compostos de pirrolopirimidina deuterados como inibidores de cdk4/6
EA200970296A1 (ru) Содержащие диариловый эфир соединения мочевины
UA102574C2 (ru) 1-фенил-2-пиридинилалкил-спиртовые производные как ингибиторы фосфодиэстеразы
MA30352B1 (fr) Pyridine [3,4-b] pyrazinones
BR0009650A (pt) Composto, composição farmacêutica, processos para inibir a secreção de uma lipoproteìna contendo apolipoproteìna b, para inibir a biossìntese de triglicerìdeos e para prevenir ou tratar hiperlipidemia, doenças arterioscleróticas e pancreatite, e, uso do composto
MA37886B1 (fr) Nouvelles pyridinones bicycliques
TW200510311A (en) CCr8 inhibitors
CO2025001998A2 (es) Formas cristalinas de un inhibidor de la pcsk9, composiciones y usos
WO2024173556A3 (en) Uses of certain 1,4-oxazepane-2-carboxamides as dpp1 inhibitors
EP1749812A4 (en) POLYMERIZATION INHIBITOR, COMPOSITIONS THEREOF, AND METHOD FOR PRODUCING A LIGHT POLYMERIZABLE COMPOUND WITH THE POLYMERIZATION INHIBITOR
TW200605865A (en) Compositions containing policosanol and HMG-Co-A reductase inhibitor and their pharmaceutical uses
SA522441650B1 (ar) مثبطات فوسفوينوسيتيد 3-كيناز الموضعية
MA32290B1 (fr) Nouvelle classe de spiro pipéridines pour le traitement de maladies neurodégénératives
EA200600879A1 (ru) Тетразольные производные и способы лечения расстройств, связанных с метаболизмом, с их помощью
PH12023550007A1 (en) Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome
NO20051011L (no) Kirale oksazol-arylpropionsyrederivater og anvendelse derav som PPAR agonister